Ocrelizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Ocrelizumab
- Pharmacist Assessment Report
- Ocrelizumab: From Progressive Multiple Sclerosis to HER2 positive breast carcinoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ocrelizumab: From Progressive Multiple Sclerosis to HER2 positive breast carcinoma
One-Sentence Summary
Ocrelizumab is an anti-CD20 antibody originally used to treat progressive multiple sclerosis. The TxGNN model predicts it may be effective for HER2-positive breast carcinoma, but there are currently 0 clinical trials and no publications that address this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Progressive multiple sclerosis |
| Predicted New Indication | HER2-positive breast carcinoma |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. From general knowledge, ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20-expressing B cells. Its efficacy in multiple sclerosis (relapsing and primary progressive forms) is well established.
The data do not support a direct mechanistic link to HER2-positive breast cancer. This cancer is driven by HER2 signalling and is not a CD20-dependent malignancy. The high TxGNN score (0.9989) is a computational prediction only. Any connection through tumour-infiltrating B cells or the immune microenvironment is speculative.
The same holds for the other top predictions, which include other breast cancer subtypes (normal breast-like, progesterone-receptor positive and negative, luminal A or B). None has clinical trials, and none has a supported mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No publications were found for HER2-positive breast carcinoma.
For the fourth-ranked prediction, luminal A or B breast tumour, 18 publications were retrieved. They are not about breast cancer. They appear to have been matched through the drug name only, and they cover ocrelizumab in multiple sclerosis and related anti-CD20 topics. The most notable are:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28002679 | 2017 | RCT | N Engl J Med | Ocrelizumab vs interferon beta-1a in relapsing MS (not breast cancer) |
| 28002688 | 2017 | RCT | N Engl J Med | Ocrelizumab vs placebo in primary progressive MS (not breast cancer) |
| 40245351 | 2025 | Phase 3 trial | Neurology | Subcutaneous vs IV ocrelizumab in MS, OCARINA II (not breast cancer) |
| 22047971 | 2011 | Phase 2 RCT | Lancet | Ocrelizumab in relapsing-remitting MS (not breast cancer) |
| 35192158 | 2022 | Review | Drugs | Review of ocrelizumab in MS (not breast cancer) |
| 35176351 | 2022 | Guidance | J Allergy Clin Immunol | Diagnosis and management of secondary hypogammaglobulinemia (not breast cancer) |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02467224 | OCREVUS | Not specified | Not specified |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interactions. The main ones listed are:
- Moderate: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone), radiopharmaceuticals (iobenguane I-131, ibritumomab tiuxetan, tositumomab, samarium-153 lexidronam), and albendazole, pentamidine and levamisole.
- Minor: zinc salts (sulfate, acetate, gluconate, chloride).
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the TxGNN model score. There are no clinical trials, no literature on breast cancer, and no supported mechanistic link. HER2-positive breast cancer is not a CD20-driven disease, and chronic B-cell depletion carries risks such as infection and hypogammaglobulinemia.
To proceed, the following is needed:
- The Health Canada package insert warnings and contraindications
- Mechanism of action data
- Preclinical or translational evidence that CD20-positive B cells play a role in HER2-positive breast cancer
- Literature that addresses ocrelizumab or anti-CD20 therapy in breast cancer
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.